全球首家获得噬菌体制剂GMP认证的企业。 本文为IPO早知道原创 作者｜ C叔 微信公众号｜ipozaozhidao 据IPO早知道消息，近日，噬菌体生物制造企业——武汉格瑞农生物科技有限公司（下称"格瑞农"） 宣布完成近亿元Pre-B轮融资，由国信弘盛领投，泰煜投资跟投，凯乘资本担任长期独家财务顾问。 融资资金将重点用于AI平台建设及工程噬菌体、噬菌肽/裂解酶等新产品研发，及动保、植保、食品 安全等多应用场景的市场拓展。 从动保、植保到食品安全和消费医疗场景的噬菌体多场景解决方案 在动保、植保业务快速放量的基础上，格瑞农正系统性地将噬菌体（噬菌肽/裂解酶）技术从养殖场 景，扩展到食品安全以及消费医疗等更广泛的应用领域。 在食品安全场景，格瑞农面向冷链、肉制品等关键环节，针对大肠杆菌、沙门氏菌、李斯特菌、空肠 弯曲杆菌等重要食源性致病菌，开发新一代生物防腐与污染控制方案，帮助企业在满足更严苛监管要 求的同时兼顾成本与口感稳定。在消费医疗领域，公司同步布局皮肤屏障受损、口腔及慢性创面管理 等方向的噬菌体与噬菌肽/裂解酶产品，为从"抗生素时代"迈向"精准微生物调控时代"提供新选择。 格瑞农创始人王喜亮表示："感谢 ...

Core Insights - Wuhan Grey Agricultural Biotechnology Co., Ltd. (Grey Agricultural) has recently completed a Pre-A+ round financing of several tens of millions, aimed at enhancing its phage technology applications and accelerating product innovation, pipeline progress, certification applications, and market promotion [1]. Group 1: Company Overview - Grey Agricultural was established in July 2019 and focuses on the research and industrialization of phage preparations, positioning itself as a global leader in phage biomanufacturing [4]. - The company has developed an international leading phage library and host bacterium library, providing significant research support and resource platforms for the industry [4]. Group 2: Product Development - Grey Agricultural's business spans animal health (livestock and aquaculture), plant protection, food safety, and consumer healthcare, with a rich product matrix [4]. - In the animal health sector, the company has developed phage solutions targeting various pathogens, significantly reducing the risk of bacterial diseases in livestock [4]. - In the plant protection sector, Grey Agricultural has launched effective biocontrol products for key crop diseases, promoting the upgrade of green agricultural technologies [4]. Group 3: Future Directions - The company aims to continue its focus on technological innovation in phage research and applications, providing high-quality products and efficient services to drive the growth of the health industry [8].

Group 1 - The core viewpoint of the news is that Wuhan Grey Agricultural Biotechnology Co., Ltd. has successfully completed a multi-million yuan Pre-A+ round of financing to enhance its phage application technology and accelerate product innovation and market promotion [1] - The company has raised nearly 100 million yuan in total through various financing rounds since its establishment in July 2019, indicating strong investor confidence and growth potential [1] - Grey Agricultural Biotechnology focuses on phage preparation research and industrialization, establishing itself as a leading global phage manufacturing platform with a comprehensive industry chain layout [1][2] Group 2 - The company has developed a diverse product matrix covering animal health, plant protection, food safety, and consumer healthcare, significantly reducing the risk of bacterial diseases in livestock [2] - The phage therapy approach is gaining traction due to its specificity, environmental friendliness, and low resistance development, positioning it as a strategic avenue in biomedicine and agriculture [6] - The management team is noted for its entrepreneurial spirit and the company's technology platform has been validated across multiple sectors, indicating a strong potential for market expansion [6][7]